OptiBiotix Health (OPTI), the former Ducat Ventures, has announced it is contracting Netherlands-based Nizo Food Research BV to undertake pre-clinical claims support for three cholesterol-lowering ‘Lactobacillus’ strains that OptiBiotix has developed.
The company added it has contracted Nizo to assess each strain's manufacturability, gastrointestinal robustness and activity against bile salts, to determine the best strain(s) to enter human studies, whilst this should also reduce the cost, timescale, and development risk for future products. With more than 60 years’ experience, Nizo has the largest food-grade pilot plant in Europe and the work is expected to be completed by the end of this year, to facilitate the commencement of human studies early next year.
The announcement saw shares in OptiBiotix up to 9.25p-10p, but they have now slipped back to a current 8.25p-9p, capitalising the company at just under £7 million.
on ShareProphets | CommentsFiled under: